Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Validation of structural brain connectivity networks: The impact of scanning parameters

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Accessibility of cortical regions to focal TES: Dependence on spatial position, safety, and practical constraints

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [11C]DASB PET study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jonas E Svensson
  • Martin Schain
  • Pontus Plavén-Sigray
  • Simon Cervenka
  • Mikael Tiger
  • Magdalena Nord
  • Christer Halldin
  • Lars Farde
  • Johan Lundberg
Vis graf over relationer

[11C]raclopride is a well established PET tracer for the quantification of dopamine 2/3 receptors (D2/3R) in the striatum. Outside of the striatum the receptor density is up to two orders of magnitude lower. In contrast to striatal binding, the characteristics of extrastriatal [11C]raclopride binding quantification has not been thoroughly described. Still, binding data for e.g., neocortex is frequently reported in the scientific literature. Here we evaluate the validity and reliability of extrastriatal [11C]raclopride binding quantification. Two sets of healthy control subjects were examined with HRRT and [11C]raclopride: (i) To assess the validity of extrastriatal [11C]raclopride binding estimates, eleven subjects were examined at baseline and after dosing with quetiapine, a D2/3R antagonist. (ii) To assess test-retest repeatability, nine subjects were examined twice. Non displaceable binding potential (BPND) was quantified using the simplified reference tissue model with cerebellum as reference. Quetiapine dosing was associated with decrease in [11C]raclopride BPND in temporal cortex (18 ± 17% occupancy) and thalamus (20 ± 17%), but not in frontal cortex. Extrastriatal occupancy was lower than in putamen (51 ± 4%). The mean absolute variation was 4-7% in the striatal regions, 17% in thalamus, and 13-59% in cortical regions. Our data indicate that [11C]raclopride PET, quantified using cerebellum as reference, is not a suitable tool to measure D2/3R in extrastriatal regions.

OriginalsprogEngelsk
TidsskriftNeuroImage
Vol/bind202
Sider (fra-til)116143
ISSN1053-8119
DOI
StatusUdgivet - 15 nov. 2019

Bibliografisk note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 59056737